Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | UGCG | Q16739 | 2/20 | 0.40 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 8/20 | 0.37 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7739141 | 1.00 | GBA1 (0.40) | GBA1UGCGGBA2NAAASPHK1 | |
| SCHEMBL7738516 | 1.00 | GBA1 (0.40) | GBA1UGCGGBA2NAAASPHK1 | |
| SCHEMBL7732765 | 1.00 | GBA1 (0.40) | GBA1UGCGGBA2NAAASPHK1 | |
| SCHEMBL7739488 | 1.00 | GBA1 (0.40) | GBA1UGCGGBA2NAAASPHK1 | |
| SCHEMBL7741596 | 0.98 | GBA1 (0.37) | GBA1UGCGGBA2NAAASPHK1 | |
| SCHEMBL12268104 | 0.93 | TSHR (0.34) | GBA1UGCGGBA2NAAASPHK1 | |
| SCHEMBL23239962 | 0.88 | TSHR (0.37) | TSHRSMN1; SMN2 | |
| SCHEMBL9906566 | 0.88 | — | — | |
| SCHEMBL577773 | 0.86 | TSHR (0.36) | TSHRSMN1; SMN2 | |
| SCHEMBL2648132 | 0.83 | ALDH1A1 (0.41) | GBA1UGCGGBA2NAAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023064366-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-9802952-B2 | Method and apparatus for the synthesis of dihydroartemisinin and artemisinin derivatives | Max-Plank-Gesellschaft zur Förderung der Wissenschaften e.v. (DE) | 2017-10-31 | — | — | US | disclosed |
| EP-3022208-B1 | METHOD AND APPARATUS FOR THE SYNTHESIS OF DIHYDROARTEMISININ AND ARTEMISININ DERIVATIVES | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS (DE) | 2017-06-14 | — | — | EP | disclosed |
| US-20160145265-A1 | METHOD AND APPARATUS FOR THE SYNTHESIS OF DIHYDROARTEMISININ AND ARTEMISININ DERIVATIVES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-05-26 | — | — | US | disclosed |
| US-6410748-B1 | Alicycli c group-containing monomer | KABUSHIKI KAISHA TOSHIBA (JP) | 2002-06-25 | — | — | US | disclosed |
| US-6291129-B1 | LIGHT SENSITIVE ELEMENT WITH UNSATURATED POLYMERS | KABUSHIKI KAISHA TOSHIBA (JP) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145265-A1 | METHOD AND APPARATUS FOR THE SYNTHESIS OF DIHYDROARTEMISININ AND ARTEMISININ DERIVATIVES | ADH1A, DHODH, DHPS | GBA1 1044/4885UGCG 1104/4885GBA2 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.